SCHEMBL6387113

SCHEMBL6387113

NC(=O)N(c1cccc(C(F)(F)F)c1)c1ccc(-c2csc3ccnc(N)c23)cc1F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EPHB4 P54760 1/20 0.48
▸ KDR P35968 19/20 0.47
▸ AURKB Q96GD4 6/20 0.47
▸ ROCK2 O75116 5/20 0.47
▸ MAP4K4 O95819 5/20 0.47
▸ LCK P06239 5/20 0.47
▸ FGFR1 P11362 5/20 0.47
▸ FLT1 P17948 5/20 0.47
▸ AXL P30530 5/20 0.47
▸ FLT3 P36888 5/20 0.47
▸ CSNK1A1 P48729 5/20 0.47
▸ CSNK1D P48730 5/20 0.47
▸ CSNK1G2 P78368 5/20 0.47
▸ MAP4K2 Q12851 5/20 0.47
▸ ROCK1 Q13464 5/20 0.47
▸ CAMK2B Q13554 5/20 0.47
▸ NTRK2 Q16620 5/20 0.47
▸ TAOK1 Q7L7X3 5/20 0.47
▸ HIPK4 Q8NE63 5/20 0.47
▸ MAP4K5 Q9Y4K4 5/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6646551 0.86 KIT (0.53) KDRAURKBROCK2MAP4K4LCK
SCHEMBL13372736 0.76 KDR (0.60) EPHB4KDRMAP4K4LCKFGFR1
SCHEMBL3528941 0.76 KDR (0.65) KDRAURKBROCK2MAP4K4LCK
SCHEMBL6687438 0.75 RORB (0.33) KDRLCK
SCHEMBL6385546 0.74 KDR (0.52) EPHB4KDRAURKBROCK2MAP4K4
SCHEMBL7131259 0.74 FLT1 (0.59) KDRAURKBROCK2MAP4K4LCK
SCHEMBL27661150 0.73 KDR (0.57) EPHB4KDRAURKBROCK2MAP4K4
SCHEMBL3527005 0.73 KDR (0.77) KDRAURKBROCK2MAP4K4LCK
SCHEMBL3526303 0.73 FLT1 (0.62) EPHB4KDRAURKBROCK2MAP4K4
SCHEMBL27640606 0.73 KDR (0.51) KDRAURKBLCKFGFR1FLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050020619-A1 Thienopyridine kinase inhibitors ABBOTT LABORATORIES 2005-01-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020619-A1 Thienopyridine kinase inhibitors ABL1, MAP4K2, MAP4K5 EPHB4 877/4885KDR 511/4885AURKB 262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback